DxTerity Earns SOC 2 Type 2 Compliance, Reinforcing Commitment to Secure Healthcare Data. Read more
  {modal url="index.php?option=com_content&view=category&layout=blog&id=18&Itemid=125" class="modalsign"}{/modal}

November 8, 2019

LabPulse also featured the news this morning, as scheduled:

November 8, 2019 -- California-based genomics company DxTerity is releasing data showing the association between type 1 interferon (IFN-1) and the development of systemic lupus erythematosus on November 11 at the American College of Rheumatology (ACR) annual meeting. The data support the commercial launch of a test for the overexpression of IFN-1, the company said.

2019 11 08 01 12 1072 DxTerity DxCollect 20191108011727
Image courtesy of DxTerity.

Lupus is a heterogeneous disease, which has presented hurdles for conducting drug trials and developing new treatments. Consequently, biomarker development is critical. The company reported that in a longitudinal study with the Oklahoma Medical Research Foundation, there was a highly significant statistical association between type 1 interferon status and risk for developing lupus. DxTerity noted that its test is already being used in clinical trials of lupus.

Meanwhile, DxTerity is gearing up to run the direct-to-patient ELEVATE study of its modular immune profile (MIP) finger-stick blood test, which includes IFN-1 screening. The company said it aims to enroll 5,000 participants.

https://www.labpulse.com/index.aspx?sec=sup&sub=gen&pag=dis&ItemID=800511

Better health management begins
at home

Subscribe to receive the latest information on new developments and products at DxTerity.